Abstract Aims-The labelling index as defined by the percentage of bone marrow plasma cells doubling their DNA in the S phase is a useful prognostic factor in multiple myeloma. The aim of this study was to examine the specificity and sensitivity of a new flow cytometric method for measuring the labelling index. Methods-Bone marrow specimens from five patients with monoclonal gammopathy of undetermined significance and 61 patients with multiple myeloma were investigated. The labelling index (LI%) was determined by means of a microscopic and flow cytometric method using the antibromodeoxyuridine antibody BU-1. Serum thymidine kinase, another index ofproliferation, was measured by radioimmunoassay.
Results-Good comparability (r=0.83) and nearly equal imprecision (CV<20%) were found with microscopic and flow cytometric methods ofLI% measurement. However, 1000 or more cells had to be counted by microscopy around the cutoff value to avoid an unacceptable imprecision. Plasma cells with increased S phase (LI%>1%) were characterised by their reduced light chain fluorescence intensity ratio between plasma cells and nonspecifically stained cells (7.9 v 14-8, p<0-002) , that is, by their generally lowered cytoplasmic immunoglobulin content. There was a moderate correlation between thymidine kinase and labelling index (r=0-56, p<0 001). At 100% specificity, myelomas with proliferating plasma cells were more sensitively detected by the labelling index than by serum thymidine kinase (55% v 32% sensitivity). Conclusions-The labelling index represents a more specific and sensitive proliferation marker than serum thymidine kinase. Flow cytometry does not result in greater precision. Prognostic factors help to assess therapeutic requirements. Survival of myeloma patients also varies according to the growth rate of tumour cells. The study of the proliferation kinetics described by the labelling index (LI%) provides a means of determining tumour growth. The labelling index describes the percentage of plasma cells in the S phase related to all counted plasma cells. A labelling index of more than 1 % has been shown to be associated with poor survival.'`The usual but time consuming method of determining proliferation is the incorporation of tritiated thymidine in the S phase DNA. Microscopic evaluation of bromodeoxyuridine uptake instead of thymidine in the S phase DNA using immunofluorescence offers a simpler means of proliferation measurement. Commonly used antibromodeoxyuridine antibodies react only with single stranded DNA which requires pretreatment with HC1 for cleavage.4 Gonchoroff et al"6 introduced the antibromodeoxyuridine antibody BU-1, avoiding denaturation of DNA due to DNase activity. Cell morphology and surface or cytoplasmic markers thus remain intact.
We tested our newly introduced flow cytometric method to determine the LI% with the aid of BU-1. This should give higher precision than microscopy because of the larger number of cells assessed. The aim of this study was to evaluate this flow cytometric method in comparison with the established microscopic method and to assess the clinical value of the LI% compared to serum thymidine kinase, which also reflects proliferation.
Methods

PATIENTS
Bone marrow specimens from 29 females and 35 males with monoclonal gammopathy (age 29-81 years) and peripheral blood samples from two patients with a plasma cell leukaemia were examined for determination of LI%.
The diagnosis of multiple myeloma was based on 1% glutamine, 0 1% penicillin-streptomycin, 10 jM bromodeoxyuridine, and 1 jM fluorodeoxyuridine.
Cells incubated without bromodeoxyuridine served as controls. The cells were washed and the dispersed pellet was fixed for 30 minutes in 70% ethanol in order to perforate the membrane. The cells were thoroughly washed twice with cold phosphate buffered saline (PBS). Twenty microlitres of a 1:4 dilution of BU-1 (a mouse antibody) were added to the 30 ,l cell suspension containing 800 000 cells, and the mixture was incubated at room temperature for 30 minutes. After washing with cold PBS, 10 jtl of fluorescein isothiocyanate (FITC) labelled goat anti-human K or k light chain antibody at 1:720 dilution (Southern Biotechnology Associates, SBA) and 10 p1 phycoerythrin (PE) labelled goat anti-mouse IgG (SBA), 1:180, were added. The cells were incubated for 30 minutes at room temperature, then washed with cold PBS; 100 p1 of PBS were added and then 50 000 cells were measured with a flow cytometer (FACScan, Becton Dickinson). The raw data were evaluated by Consort 30 software (Becton Dickinson).
The fluorescence profile, that is, the graph showing fluorescence intensity versus the number of counted cells, defined a clear cutoff point: the minimum between the two peaks generated by specifically and non-specifically stained cells was chosen for each fluorescence range. Plasma cells were identified by the higher fluorescence intensity of the FITC labelled cells. The procedure was the same for the control sample data. Four panels were established on the two-colour fluorescence display using these cutoff values which permitted determination of the number of cells counted for each panel (fig 1) , and the preliminary LI% was calculated. The final LI% was obtained from the difference between the preliminary LI% of the bromodeoxyuridine incubated cells and the control sample cells. The signal to noise ratio, that is, the ratio of the preliminary LI% of the bromodeoxyuridine incubated cells and the control sample cells, had to exceed 2. Otherwise the final LI% was fixed as 0. In each category (labelling index <2% or >2%) bone marrow of four patients was examined. At least 500 plasma cells and 1000 plasma cells were microscopically counted six and three times, respectively. Bone marrow of two or three patients was analysed in each described category to determine imprecision of flow cytometric measurement. In one series, because of limitations of cell quantity of the aspirate, repeated measurements were made only a few times.
Zeiss fluorescence microscope. S phase plasma cells were then detected by simultaneous identification of green cytoplasmic light chains forming a ring around the red nucleus of the cell. 1 -0% for flow cytonletry, four cases were not identically described by low or high levels of proliferating plasma cells. If more than 1 -0% proliferating plasma cells were found by the flow cytometric method the cytoplasmic immunoglobulin content as revealed by the RFI was significantly reduced (p = 0-002, RFI = 7 9, cy = 5 1, n = 13 v RFI = 14-8, ca = 8'6, n = 29).
This was also true for the untreated patients or patients treated at least eight months ago (n=29, p=001). Degree of plasma cell infiltration estimated by bone marrow biopsy did not affect cytoplasmic immunoglobulin content expressed as RFI (n=35, p=0 09).
Thymidine kinase Serum samples were measured six times to determine intra-assay and interassay imprecision of thymidine kinase measurements. Imprecision was reflected by an intra-assay CV of 5% and an interassay CV of 6% for values >8U/1 and <17 U/1.
DEFINING CUTOFF VALUES OF LI% AND THYMIDINE KINASE
Patients with MGUS and smouldering myeloma had in common a labelling index of less than 0-8%. A thymidine kinase activity of 16 U/1 was set as the 100% specific cutoff value for MGUS or smouldering myeloma, as was found in the 25 patients with these conditions (data not shown).
DIAGNOSTIC SENSITIVITY
There was a significant difference in the proliferation kinetics for inactive and active disease (p<0001) (fig 3) . Defining the cutoff value on the basis of 100% specificity versus the inactive forms of monoclonal gammopathy (labelling index <0 8%) gave a 57% sensitivity for active untreated myelomas. Four of seven non-responding patients showed a high S phase fraction in the plasma cells. Our analyses showed a moderate but significant correlation between thymidine kinase and LI% (r=0-56, p<0-001, n=35): 32% of patients (7/22) We found a significant inverse correlation between cytoplasmic immunoglobulin content and proliferation of plasma cells. A varying cytoplasmic immunoglobulin content can influence the precision of the flow cytometric method in proliferating myelomas. Total separation of plasma cells from non-specifically stained cells may sometimes be difficult. The very high density of CD 38 on the surface specifically characterises mature plasma cells, but cytoplasmic light chains acting as a plasma cell marker may not be replaced by CD 38. The prognostically relevant pre-plasma-cells would not be detected. 14 15 The antagonising effect ofcytokines inducing mainly proliferation or immunoglobulin production may explain why plasma cells with increased S phase are generally characterised by a lowered immunoglobulin content. '6 In treated cases therapy not only destroys myeloma cells but possibly diminishes immunoglobulin synthesis of the remaining plasma cells. Infiltration quantity did not influence immunoglobulin content of the plasma cells.
In conclusion, both methods showed good comparability, but methodological and biological effects prevented us from achieving the reduced imprecision which we had hoped for with the flow cytometry method. In certain cases morphological recognition of proliferating plasma cells allows a more reliable determination ofthe labelling index. Laser scan microscopy could combine the advantages of microscopy and flow cytometry.
The moderate correlation between serum thymidine kinase and the labelling index, as previously shown,'718 is not surprising. Thymidine kinase is the key enzyme of the salvage pathway for DNA synthesis, and reutilisation of endogenous thymidine is linked to proliferation. The false nucleotide and thymidine analogue bromodeoxyuridine is inserted by this enzyme, but thymidine kinase and the labelling index are not equivalent from a diagnostic point of view. An important advantage of the proliferation index is the high specificity of the measurement, whereas thymidine kinase is influenced by viral diseases, circadian fluc- 
